Contents

1 Clinical Use of Aromatase Inhibitors in Breast Cancer: History and Present 1
David Cameron
Introduction 1
From Beatson to Aromatase Inhibitors 2
Current Situation 4
Neo-Adjuvant Setting 5
Adjuvant Setting 5
Advanced Disease 6
Resistance to Aromatase Inhibition 7
Conclusion 8
References 9

2 Structure, Regulation and Polymorphisms of the Aromatase Gene 13
Nobuhiro Harada
Introduction: Tissue-Specific Expression of Human Aromatase 14
Structure of the Human Aromatase Gene 15
Expression of Aromatase in Breast Cancer Stroma 17
Transcriptional Regulation of the Aromatase Gene in Breast Cancer Tissues 20
Epigenetic Regulation of Aromatase 23
Genetic Polymorphisms of the Human Aromatase Gene Associated with AI Response and Susceptibility to Breast Cancer 23
Post-transcriptional Regulation of Aromatase 25
Other Possible Factors that Affect Aromatase 26
Conclusion 26
References 26

3 Structure, Function and Inhibition of Aromatase 33
Debashis Ghosh, Jessica Lo and Chinaza Egbuta
Introduction 34

Crystal Structure of Human Placental Aromatase 35
Architecture of the Active Site 37
Structural Perspective on the Mechanism of Action 39
Membrane Integration 42
Oligomerization of Aromatase 44
Roles of Critical Residues 46
Motion and Flexibility of the Aromatase Molecule 48
Aromatase Inhibitors: Recent Developments 50
Phosphorylation of Aromatase and Estrogen Signaling: The New Frontier 53
Concluding Remarks 55
References 56

4 In Vivo Models of AI Resistance 63
Gauri Sabnis and Angela Brodie
Introduction 64
Carcinogen Induced Syngeneic Tumor Model 65
Xenograft Model Using the Nude Mouse 67
Intra-tumoral Aromatase Xenograft Model 67
Aromatase Inhibitors as First Line Agents 69
AI Resistance Models 72
Estrogen Deprivation Based Models 72
Letrozole Resistance Model 74
Other Models 79
Variations Between the Models of AI Resistance 80
Discrepancies Between Animal Models and Clinical Data 80
Conclusion 80
References 82

5 Ineffective Inhibition of Aromatase: A Cause for AI Resistance? 87
Per E. Lønning
Introduction 88
The Aromatase Enzyme and Estrogen Disposition in Postmenopausal Women 88
Plasma Estrogen Measurements in Relation to Treatment with Aromatase Inhibitors 90
Tracer Studies 92
Tissue Estrogen Levels 92
Conclusions 95
References 95

6 Understanding the New Biology of Estrogen-Induced Apoptosis and Its Application in Patient Care 101
Elizabeth E. Sweeney and V. Craig Jordan
Introduction 102

Selective Estrogen Receptor Modulators (SERMs) 103
Contribution of SERM Resistance in Understanding Estrogen-Induced Apoptosis 103
Long-Term Estrogen Deprivation 104
Molecular Mechanisms of Estrogen-Induced Apoptosis. 105
Estrogen-Induced Apoptosis: Clinical Translation Opportunities. 106
Perspectives and Conclusions 109
References 110

7 Ligand-Independent Signalling Through Estrogen Receptor Pathways in Breast Cancer. 115
Jean McBryan and Leonie S. Young
Introduction 116
Background: Classical Ligand-Dependent Estrogen Receptor Signalling. 116
ER Phosphorylation. 118
Ligand-Independent Phosphorylation of Serine 118 118
Ligand-Independent Phosphorylation of Other Sites. 120
ER Phosphorylation as a Marker of AI Resistance 121
Targeting ER Phosphorylation in Breast Cancer Treatment 123
Role of Co-factors in Ligand-Independent ER Signalling 126
Hyper-sensitivity to Low Concentrations of Ligand 127
Amplification and Overexpression of ER 129
Activation of ER by Alternative Ligands 130
Challenges in Detecting Persistent ER Signalling 131
Approaches to Combat Ligand-Independent ER Signalling 132
Conclusions 133
References 134

8 Chromatin and Epigenetic Determinants of Resistance to Aromatase Inhibitors 145
Raffaella Maria Gadaleta and Luca Magnani
Introduction 146
On Epigenetics, Chromatin and Regulatory Elements 147
Genomics, Epigenetics and Transcriptional Regulation of Aromatase Gene 149
The Chromatin Landscape and Its Interaction with the Estrogen Receptor α, in the Context of Aromatase Inhibitor Resistance. 152
Alternative Ligands and Ligand-Independent ER-Activation: Role in Reprogramming of ERα Binding to the Chromatin Template 155
Epigenetic Modulation of ER Expression and Alternative Survival Pathways in AI Resistant Models 156
Genetic-Epigenetic Crosstalk in AI Resistance. 158
Epigenetic Intervention in the Context of Aromatase Inhibitor Resistance 159

Consideration on Epigenomics Studies in Cell Lines and Tumour Heterogeneity 160
Future Perspective 160
References 161

9 Aromatase Inhibitor Resistance via Non-endocrine Signalling Pathways 169
Abdul Aziz Bin Aiderus and Anita K. Dunbier
Introduction 170
In Vitro Models of AI Resistance 170
Cell Intrinsic and Extrinsic Mechanisms of Resistance 171
Cell Intrinsic Mechanisms 172
Alternative Signalling Pathways Associated with Aromatase Inhibitor Resistance 172
Cell Cycle-Related Resistance Mechanisms 180
Tumour Microenvironment as a Mediator of Endocrine Treatment Resistance 182
Inflammatory Immune Profile Correlates with Poor Response to Neoadjuvant AI Treatment 182
Adipocytes as a Driver of Oestrogen-Dependent Growth 183
Future Directions 184
References 184

10 Prediction of Response to Aromatase Inhibitors in Breast Cancer 191
Alexey A. Larionov and William R. Miller
Introduction 192
Confounding Factors in Predicting Endocrine Response 192
Response Assessment in Different Clinical Settings 193
Types of Response 195
Biomarker's Development and Levels of Evidence 197
Routinely Measured Molecular Markers 198
Oestrogen Receptor 198
Progesterone Receptor and HER2 200
Ki67 201
Multigene Transcriptional Signatures and Multicomponent Clinical Indices 202
Making a Multi-gene Signature 202
Intrinsic Subtypes 203
Oncotype Dx 204
Adjuvant Endocrine Signatures and Clinical Indices 205
Signatures to Predict Neo-adjuvant Response to AIs 207
Emerging Technologies and Markers 211
Pharmacogenetic Markers 212
Monitoring of AIs Concentration and Estrogens in Blood 213

Multi-pathway Panels to Detect Mechanisms of Resistance 213
New Molecular Methods and Bioinformatics Resources. 215
Conclusion. 216
References 217

11 Clinical Trials Combining Aromatase Inhibitors with Other Targeted Treatments 229
Hazel Lote and Stephen Johnston
Introduction 230
AIs—Background 232
AIs + Anti-HER2 Therapy 232
Overcoming Primary Resistance Due to HER2 Over-Expression 233
Delaying Secondary Resistance Due to HER2 Over-Expression 236
AIs + EGFR Targeted Therapy. 236
AIs + mTOR Pathway Inhibitors 237
Overcoming Secondary Resistance by mTOR Inhibition 237
Biological Feedback in the PI3K/Akt/mTOR Pathway. 238
AIs + PI3K Inhibitors. 241
AIs + PI3K/mTOR Combined Blockade 241
AIs + Akt Inhibitors 241
AIs in Combination with Inhibition of Cyclin-Dependent Kinase (CDK) 4/6 242
Agents Targeting FGFR. 243
AIs and Histone Deacetylase Inhibitors (HDACI) 247
AIs and Anti-angiogenic Agents 247
AIs in Combination with Agents Targeting Insulin-Like Growth Factor Type 1 (IGF-1) 249
Proteosome Inhibitors Targeting NF-κB 252
Agents Targeting Src Kinase 252
Future Directions. 253
Conclusion. 254
References 254

12 Aromatase Inhibitors Beyond Breast Cancer: Endometrium Versus Breast Puzzle and Other Issues. 261
Lev M. Berstein
Introduction 262
AIs in Cancer. 262
Let's Start from Breast Cancer. 262
Endometrial Cancer (EC). 264
Ovarian Cancer. 268
Lung Cancer. 271
Other Tumors 272
Non-cancer Conditions 273
Endometriosis. 273

Infertility 274
Medical Abortion 275
Gynecomastia 275
Other Conditions 275
Conclusions and Perspectives 276
References 278

Index 287

http://www.springer.com/978-3-319-17971-1

Resistance to Aromatase Inhibitors in Breast Cancer
Larionov, A. (Ed.)
2015, XVI, 288 p. 56 illus., 27 illus. in color., Hardcover
ISBN: 978-3-319-17971-1